文献速递慢性肾脏病血液净化与透析

透析与非透析CKD患者心力衰竭的10年趋势

10-Year Trends in Heart Failure Among Patients With Dialysis and Nondialysis CKD.
PubMed 文献 · Kidney Int Rep · 2026-07-04

该研究基于瑞典肾脏登记2011-2021年数据,纳入非透析CKD G4(n=25591)、G5(n=13968)、血液透析(n=10635)和腹膜透析(n=4511)患者,分析心衰相关住院与死亡趋势。结果显示心衰住院率随CKD分期加重而升高,为一般人群的3.7至6.8倍;十年间非透析CKD和血透患者心衰住院率分别增加51%、36%和30%,而心衰死亡率下降但慢于一般人群。

要点

  • 晚期CKD患者心衰住院率是一般人群的3.7-6.8倍,且随CKD分期加重而升高。
  • 2011-2021年CKD G4、G5非透析和血透患者心衰住院率分别增加51%、36%和30%。
  • 非透析CKD和透析患者心衰死亡率下降,但降幅慢于一般人群。

核心结论

  • 过去十年晚期CKD患者心衰住院率大幅上升且增速快于一般人群,心衰死亡率虽下降但慢于一般人群,提示CKD中心衰负担加重。

研究设计与样本

  • 基于瑞典肾脏登记2011-2021年数据的队列研究,纳入非透析CKD G4(n=25591)和G5(n=13968)、血液透析(n=10635)和腹膜透析(n=4511)患者。
  • 采用泊松模型估计未调整及按年龄性别匹配一般人群标准化的心衰住院和死亡发生率。

主要发现

  • 心衰相关住院率随CKD分期加重而升高,为一般人群的3.7至6.8倍。
  • 2011至2021年间,CKD G4、G5非透析和血透患者心衰住院率分别增加51%、36%和30%,增幅大于一般人群。
  • 非透析CKD和透析依赖CKD患者心衰死亡率持续下降,CKD G4降幅达20.8%,血透降幅达66%,但降幅慢于一般人群。
  • RASi和β受体阻滞剂使用率保持稳定且相对较低(RASi为44.5%至70%),非透析CKD利尿剂处方下降。

临床怎么用

  • 应加强对晚期CKD患者心衰的预防和管理,关注心衰住院率上升趋势。
  • 尽管心衰死亡率下降,但降幅慢于一般人群,需优化CKD患者心衰治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study explores the rates and temporal trends of heart failure (HF) in advanced chronic kidney disease (CKD) compared with the general population (GP). METHODS: We included all patients with nondialysis dependent CKD stage G4 (n = 25,591) and G5 (n = 13,968), on hemodialysis (HD; n = 10,635) and peritoneal dialysis (PD; n = 4511) enrolled in the Swedish Renal Registry during 2011 and 2021. Outcomes included HF-related hospitalization and HF-related mortality. Patients were followed until the event, death, or progression to a more severe CKD-stage and/or change of dialysis modality. Poisson models were used to estimate unadjusted incidence rates (IR) and IR standardized to an age- sex-matched GP. RESULTS: Rates of HF-related hospitalization increased with more advanced stages of CKD, ranging from 3.7 to 6.8 times higher than those in the GP. Between 2011 and 2021, renin-angiotensin system inhibitor (RASi) and beta-blocker use remained stable and relatively low (44.5% to 70% for RASi), whereas diuretic prescription declined in nondialysis (ND)-CKD. This paralleled an important increase in the rates of HF-related hospitalization in CKD stage 4 (+51%), 5-ND (+36%), and HD (+30%), with a larger increase than that observed in the GP. In contrast, HF-related mortality steadily declined in both ND-CKD (up to -20.8% in CKD stage 4) and dialysis dependent CKD (up to -66% in HD), although slower than in the GP. CONCLUSION: Despite decline in HF-related mortality over the past decade-although slower than in the GP-HF-related hospitalization rates have risen substantially in advanced CKD, with a faster increase than those in the GP. These findings highlight the growing HF burden in CKD, and the need for targeted prevention and management strategies.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Lankinen R, Murata S, Carrero JJ, et al. 10-Year Trends in Heart Failure Among Patients With Dialysis and Nondialysis CKD. Kidney Int Rep. 2026. PMID: 42577027. doi:10.1016/j.ekir.2026.106695

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。